Given the delay, an additional 14-day cycle of venetoclax/azacitidine was administered, a duration demonstrating similar efficacy and reduced myelosuppression relative to the conventional 28-day cycle in a study of elderly patients with AML.35 After the second cycle, the BM showed MRD negativity by flow cytometry; peripheral blood showed low level NPM1 PCR positivity (ratio of 0.0056). Here, NPM1 is linked to acute myeloid leukemia.